New Guidelines Have Potential to Transform the TB Treatment Landscape with Six-Month Standard PRETORIA (3 May 2022)—TB Alliance applauds today’s
Imagining a TB-free world amidst resurgence during COVID-19 pandemic NEW YORK (March 24, 2022)—The world continues to battle against two
NEW YORK (February 2, 2022)—TB Alliance today announced the appointment of Maria Beumont, MD to the position of Vice President,
NEW YORK (January 27, 2022)—The 2021 G-Finder Report, released today, shows that low funding levels continue to encumber the pursuit
NEW YORK, NY (20 January 2022) — Today, TB Alliance announced that it has received funding from the United States Agency for
(BERLIN/GENEVA, 13 January 2022) – The German Federal Ministry of Education and Research (BMBF) through KfW has granted additional funding to
TaBriX is a new spin-out company from The University of Manchester (UoM) with the mission to create novel anti-virulence drugs
TBAJ-587-CL-001 is the first Phase 1 trial in humans conducted by TB Alliance through the European Regimen Accelerator for Tuberculosis
New results from operational research in Ukraine and MSF’s TB-PRACTECAL study on drug-resistant forms of tuberculosis to be presented PRETORIA
“We have seen a number of highly promising breakthroughs in tuberculosis (TB) drug development over the past few years, but
